Form 4: Eliem Therapeutics EVP Valerie Morisset Sells Shares
SEC Form 4
Valerie Morisset, EVP, R&D and CSO of Eliem Therapeutics, Inc., sold a portion of her holdings in two transactions on July 17 and 18, 2024.
Summary
- Valerie Morisset, the EVP, R&D and CSO of Eliem Therapeutics, Inc. (ELYM), reported changes in beneficial ownership.
- On July 17, 2024, Morisset sold 3,207 shares of Common Stock at a price of $6.91 per share.
- On July 18, 2024, Morisset sold 38,576 shares of Common Stock at a price of $6.93 per share.
- Following these transactions, Morisset directly owns 160,523 shares of Eliem Therapeutics, Inc.
Sentiment
Score: 5
Explanation: The document is a standard SEC filing reporting stock sales by an executive, which is a neutral event. It doesn't inherently indicate positive or negative sentiment about the company's prospects.
Industry Context
Form 4 filings are standard disclosures required by the SEC when company insiders, like executives or directors, trade their company's stock. These filings provide transparency into the transactions of those with privileged information.
Stakeholder Impact
- Shareholders may interpret insider selling in various ways, potentially leading to speculation about the company's future performance.
Key Dates
| Date | Description |
|---|---|
| 07/17/2024 | Sale of 3,207 shares of Common Stock at $6.91 per share. |
| 07/18/2024 | Sale of 38,576 shares of Common Stock at $6.93 per share. |
| 07/19/2024 | Date of signature on the Form 4 filing. |
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.